Lilly Zyprexa Risk - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

How Well Do You Know Your Bird?
Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.
A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

Report: Eli Lilly Said to Play Down Risk

Topics:Pharmaceuticals

Companies:Eli Lilly and Company

By: AP | 18 Dec 2006 | 02:20 PM ET

Text Size

NEW YORK - Eli Lilly has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its Web site Sunday, citing internal documents from the drug maker and e-mail messages of its managers.

The documents, obtained from a lawyer for mentally ill patients, show Lilly [LLY Loading... () ] executives kept data from doctors about the drug's tendencies to promote obesity and boost blood sugar, the newspaper said.

Zyprexa is Lilly's best-selling product. With sales of $4.2 billion last year, about 2 million people worldwide were taking the drug.

Thirty percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, and some patients have reported putting on more than 100 pounds, according to information published by Lilly. But the internal documents, which cover the period from 1995 to 2004, show Lilly feared sales would be hurt if the company was open with doctors the drug's side effects, the paper said.

Lilly denied there was a connection between the drug and diabetes on Friday in a written response to questions about the documents, according to The New York Times. The drug maker said the documents had been taken out of context, the newspaper said.